Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : (Record no. 47330)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07595cam a2200817 i 4500 |
| 001 - CONTROL NUMBER | |
| control field | ocn927362841 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20200827105145.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d f |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr un||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 151202s2015 dcua obt 100 0 eng |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | NLM |
| Modifying agency | CUS |
| -- | MMU |
| -- | N$T |
| -- | YDXCP |
| -- | EBLCP |
| -- | UAB |
| -- | BUF |
| -- | OCLCF |
| -- | OCLCO |
| -- | OCLCQ |
| -- | EZ9 |
| -- | OCLCA |
| -- | OCLCQ |
| -- | OCLCO |
| -- | WYU |
| -- | NLM |
| -- | OCLCO |
| -- | OCLCA |
| -- | OCLCQ |
| -- | OCLCO |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER | |
| Record control number | 101673538 |
| Source | DNLM |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780309373241 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 0309373247 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780309373234 |
| Qualifying information | (paperback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 0309373239 |
| Qualifying information | (paperback) |
| 029 0# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | NLM |
| System control number | 101673538 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | DEBBG |
| System control number | BV044026931 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)927362841 |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | pcc |
| 043 ## - GEOGRAPHIC AREA CODE | |
| Geographic area code | n-us--- |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.25 |
| Item number | .N67 2015 |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | 2016 C-538 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | QV 76.5 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 071000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| Edition number | 23 |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 111 2# - MAIN ENTRY--MEETING NAME | |
| Meeting name or jurisdiction name as entry element | Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) |
| Date of meeting or treaty signing | (2015 : |
| Location of meeting | Washington, D.C.), |
| Relator term | author. |
| Authority record control number or standard number | http://id.loc.gov/authorities/names/no2015147304 |
| 245 10 - TITLE STATEMENT | |
| Title | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : |
| Remainder of title | workshop summary / |
| Statement of responsibility, etc. | Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Washington, D.C. : |
| Name of producer, publisher, distributor, manufacturer | National Academies Press, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 PDF file (xiv, 114 pages)) : |
| Other physical details | illustrations |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Title from PDF title page. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Includes bibliographical references. |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc. | The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop. |
| 536 ## - FUNDING INFORMATION NOTE | |
| Text of note | This project was supported by contracts between the National Academy of Sciences and AbbVie; the Alzheimer's Association; American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Brain Canada Foundation; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; the Department of Health and Human Services' Food and Drug Administration (Contract No. 1R13FD005154-01) and National Institutes of Health (NIH, Contract Nos. HHSN26300026 and HHSN263201200074I, Task Order HHSN26300023 [Under Master Base #DHHS-10001292]) through the National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Disease, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly and Company; FasterCures; Foundation for the National Institutes of Health; Friends of Cancer Research; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc. (Contract No. 005319); Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck & Co., Inc. (Contract No. CMO-141224-000649); The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. BCS-1064270); New England Journal of Medicine; One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited (Contract No. 53108); and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Version viewed December 21, 2015. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | eBooks on EBSCOhost |
| Provenance (VM) [OBSOLETE] | EBSCO eBook Subscription Academic Collection - Worldwide |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug development |
| General subdivision | Economic aspects |
| Form subdivision | Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Central nervous system |
| General subdivision | Diseases |
| -- | Effect of drugs on |
| Form subdivision | Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical industry |
| General subdivision | Economic aspects |
| Form subdivision | Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Public-private sector cooperation |
| Form subdivision | Congresses. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Central Nervous System Agents |
| General subdivision | economics. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D002491Q000191 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Discovery |
| General subdivision | economics. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D055808Q000191 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Financial Support. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D005378 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nervous System Diseases |
| General subdivision | drug therapy. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D009422Q000188 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nervous System Diseases |
| General subdivision | economics. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D009422Q000191 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Private Sector |
| General subdivision | economics. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D017149Q000191 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | MEDICAL |
| General subdivision | Pharmacology. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical industry |
| General subdivision | Economic aspects. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst01060138 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Public-private sector cooperation. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst01083445 |
| 655 #2 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Congress. |
| Authority record control number or standard number | https://id.nlm.nih.gov/mesh/D016423 |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 655 #7 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Conference papers and proceedings. |
| Source of term | fast |
| Authority record control number or standard number | (OCoLC)fst01423772 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Norris, Sheena M. Posey, |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Strauss, Evelyn, |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | De Feo, Christopher Joseph, |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stroud, Clare, |
| Relator term | author. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Institute of Medicine (U.S.). |
| Subordinate unit | Forum on Neuroscience and Nervous System Disorders, |
| Relator term | sponsoring body. |
| Authority record control number or standard number | http://id.loc.gov/authorities/names/no2008032406 |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Institute of Medicine (U.S.). |
| Subordinate unit | Forum on Drug Discovery, Development, and Translation, |
| Relator term | sponsoring body. |
| Authority record control number or standard number | http://id.loc.gov/authorities/names/no2007051854 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders. |
| Place, publisher, and date of publication | Washington, D.C. : National Academies Press, [2015] |
| International Standard Book Number | 0309373239 |
| Record control number | (OCoLC)921241584 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://libproxy.firstcity.edu.my:8443/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476">https://libproxy.firstcity.edu.my:8443/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476</a> |
| 938 ## - | |
| -- | EBL - Ebook Library |
| -- | EBLB |
| -- | EBL4393789 |
| 938 ## - | |
| -- | EBSCOhost |
| -- | EBSC |
| -- | 1029476 |
| 938 ## - | |
| -- | YBP Library Services |
| -- | YANK |
| -- | 12724313 |
| 994 ## - | |
| -- | 92 |
| -- | MYFCU |
No items available.